{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T20:36:30Z","timestamp":1772051790944,"version":"3.50.1"},"reference-count":36,"publisher":"Institute of Physiology of the Czech Academy of Sciences","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"published-print":{"date-parts":[[2015,11,30]]},"abstract":"<jats:p>Moderately elevated plasma\/serum triglycerides (2-10 mmol\/l) signalize increased risk for cardiovascular disease or presence of non-alcoholic steatohepatitis. Extremely elevated triglycerides (more than 10 mmol\/l) signalize increased risk for pancreatitis and lipemia retinalis. The concentration of triglycerides is regulated by many genetic and nongenetic factors. Extremely elevated triglycerides not provoked by nutritional factors, especially inappropriate alcohol intake are more likely to have a monogenic cause. On the contrary, mildly to moderately elevated triglycerides are often caused by polygenic disorders; these could be also associated with central obesity, insulin resistance, and diabetes mellitus. Concentration of triglycerides is also closely interconnected with presence of atherogenic remnant lipoproteins, impaired reverse cholesterol transport and more atherogenic small LDL particles. In general, there is tight association between triglycerides and many other metabolic factors including intermediate products of lipoprotein metabolism which are frequently atherogenic. Therefore, reliable evaluation of the independent role of triglycerides especially in atherosclerosis and cardiovascular disease is difficult. In individual cases values of HDL cholesterol, non-HDL cholesterol (total minus HDL cholesterol), non-HDL\/nonLDL cholesterol (total minus HDL minus LDL cholesterol, especially in nonfasting status), atherogenic index of plasma and\/or apolipoprotein B could help in decisions regarding aggressiveness of treatment.<\/jats:p>","DOI":"10.33549\/physiolres.933196","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T11:53:34Z","timestamp":1587556414000},"page":"S323-S330","source":"Crossref","is-referenced-by-count":19,"title":["Fasting and Nonfasting Triglycerides in Cardiovascular and Other Diseases"],"prefix":"10.33549","author":[{"given":"J.","family":"PI\u0164HA","sequence":"first","affiliation":[{"name":"Laboratory for Atherosclerosis Research, Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"KOV\u00c1\u0158","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"BLAHOV\u00c1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"19169","published-online":{"date-parts":[[2015,11,18]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"AUSTIN MA: Epidemiology of hypertriglyceridemia and cardiovascular disease. Am J Cardiol 83: 13F-16F, 1999.","DOI":"10.1016\/S0002-9149(99)00209-X"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"BANSAL S, BURING JE, RIFAI N, MORA S, SACKS FM, RIDKER PM: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298: 1309-1316, 2007.","DOI":"10.1001\/jama.298.3.309"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"BOR\u00c9N J, WATTS GF, ADIELS M, S\u00d6DERLUND S, CHAN DC, HAKKARAINEN A, LUNDBOM N, MATIKAINEN N, KAHRI J, VERG\u00c8S B, BARRETT PH, TASKINEN MR: Kinetic and related determinants of plasma triglyceride concentration in abdominal obesity: multicenter tracer kinetic study. Arterioscler Thromb Vasc Biol 35: 2218-2224, 2015.","DOI":"10.1161\/atvbaha.115.305614"},{"key":"ref3","unstructured":"DOBI\u00c1SOV\u00c1 M: AIP - atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice (in Czech). Vnitr Lek 52: 64-71, 2006."},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"DOBI\u00c1SOV\u00c1 M, FROHLICH J, SEDOV\u00c1 M, CHEUNG MC, BROWN BG: Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J Lipid Res 52: 566-571, 2011.","DOI":"10.1194\/jlr.p011668"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"FRED HL, ACCAD M: Lipemia retinalis. N Eng J Med 340: 1969, 1999.","DOI":"10.1056\/NEJM199906243402506"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"FROHLICH J, DOBIASOVA M, LEAR S, LEE KW: The role of risk factors in the development of atherosclerosis. Crit Rev Clin Lab Sci 38: 401-440, 2001.","DOI":"10.1080\/20014091084245"},{"key":"ref7","unstructured":"HAVEL RJ: Pathogenesis, differentiation and management of hypertriglyceridemia. Adv Intern Med 15: 117-154, 1969."},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"HAVEL RJ: Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol 5: 102-109, 1994.","DOI":"10.1097\/00041433-199404000-00006"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"HEGELE RA, GINSBERG HN, CHAPMAN MJ, NORDESTGAARD BG, KUIVENHOVEN JA, AVERNA M, BOR\u00c9N J, BRUCKERT E, CATAPANO AL, DESCAMPS OS, HOVINGH GK, HUMPHRIES SE, KOVANEN PT, MASANA L, PAJUKANTA P, PARHOFER KG, RAAL FJ, RAY KK, SANTOS RD, STALENHOEF AF, STROES E, TASKINEN MR, TYBJ\u00c6RG-HANSEN A, WATTS GF, WIKLUND O; EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS PANEL: Lancet Diabetes Endocrinol 2: 655-666, 2014.","DOI":"10.1093\/eurheartj\/ehu274"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"HOKANSON JE, AUSTIN MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a metaanalysis of population-based prospective studies. J Cardiovasc Risk 3: 213-219, 1996.","DOI":"10.1177\/174182679600300214"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"JACOME-SOSA MM, PARKS EJ: Fatty acid sources and their fluxes as they contribute to plasma triglyceride concentrations and fatty liver in humans. Curr Opin Lipidol 25: 213-220, 2014.","DOI":"10.1097\/mol.0000000000000080"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"KOVAR J, ZEMANKOVA K: Moderate alcohol consumption and triglyceridemia. Physiol Res 64 (Suppl 3): S371-S375, 2015.","DOI":"10.1016\/j.metabol.2015.08.016"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"LIBBY P: Triglycerides on the rise: should we swap seats on the seesaw? Eur Heart J 36: 774-776, 2015.","DOI":"10.1093\/eurheartj\/ehu500"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"MCNAMARA JR, SHAH PK, NAKAJIMA K, CUPPLES LA, WILSON PW, ORDOVAS JM, SCHAEFER EJ: Remnant-like (RLP) cholesterol is an independent cardiovascular risk factor in women: results from the Framingham Heart Study. Atherosclerosis 154: 229-236, 2001.","DOI":"10.1016\/s0021-9150(00)00484-6"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"NAKAJIMA K, OKAZAKI M, TANAKA A, PULLINGER CR, WANG T, NAKANO T, ADACHI M, HAVEL RJ: Separation and determination of remnant-like particles in human serum using monoclonal antibodies to Apo B-100 and Apo A-1. J Clin Ligand Assay 19: 177-183, 1996.","DOI":"10.1016\/0009-8981(93)90062-9"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"NAKANO T, TOKITA Y, NAGAMINE T, TANAKA A, OKAZAKI M, YATSUZUKA S, TAMEI N, SHIMOMURA Y, ANDO Y, AKAMATSU S, FUJITA MQ, NAKAJIMA K: Measurement of serum remnant-like lipoprotein particle-triglyceride (RLP-TG) and RLP-TG\/total TG ratio using highly sensitive triglyceride assay reagent. Clin Chim Acta 412: 71-78, 2011.","DOI":"10.1016\/j.cca.2010.09.040"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"NORDESTGAARD BG, BENN M, SCHNOHR P, TYBJAERG-HANSEN A: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298: 299-308, 2007.","DOI":"10.1001\/jama.298.3.299"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"NORDESTGAARD BG, VARBO A: Triglycerides and cardiovascular disease. Lancet 384: 626-635, 2014.","DOI":"10.1016\/s0140-6736(14)61177-6"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"PATEL A, BARZI F, JAMROZIK K, LAM TH, UESHIMA H, WHITLOCK G, WOODWARD M; ASIA PACIFIC COHORT STUDIES COLLABORATION: Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 110: 2678-2686, 2004.","DOI":"10.1161\/01.cir.0000145615.33955.83"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"PI\u0164HA J, KOV\u00c1\u0158 J, \u0160KODOV\u00c1 Z, C\u00cdFKOV\u00c1 R, ST\u00c1VEK P, \u010cERVENKA L, \u0160EJDA T, L\u00c1NSK\u00c1 V, POLEDNE R: Association of intima-media thickness of carotid arteries with remnant lipoproteins in men and women. Physiol Res 64 (Suppl 3): S377-S384, 2015.","DOI":"10.1016\/s0021-9150(99)80494-8"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"POLLIN TI, DAMCOTT CM, SHEN H, OTT SH, SHELTON J, HORENSTEIN RB, POST W, MCLENITHAN JC, BIELAK LF, PEYSER PA, MITCHELL BD, MILLER M, O'CONNELL JR, SHULDINER AR: A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 322: 1702-1705, 2008.","DOI":"10.1126\/science.1161524"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"RAJAMANI K, COLMAN PG, LI LP, BEST JD, VOYSEY M, D'EMDEN MC, LAAKSO M, BAKER JR, KEECH AC; FIELD STUDY INVESTIGATORS: Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 373: 1780-1788, 2009.","DOI":"10.1016\/s0140-6736(09)60698-x"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"RUTLEDGE JC, NG KF, AUNG HH, WILSON DW: Role of triglyceride-rich lipoproteins in diabetic nephropathy. Nat Rev Nephrol 6: 361-370, 2010.","DOI":"10.1038\/nrneph.2010.59"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"SACKS FM: The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia. Curr Opin Lipidol 26: 56-63, 2015.","DOI":"10.1097\/mol.0000000000000146"},{"key":"ref25","unstructured":"ST\u00c1VEK P, PI\u0164HA J, POLEDNE R: Small, density lipoprotein particles - methods and risk in Czech population (in Czech). Klin Biochem Metab 27: 68-71, 1998."},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"THOMSEN M, VARBO A, TYBJ\u00c6RG-HANSEN A, NORDESTGAARD BG: Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study. Clin Chem 60: 737-746, 2014.","DOI":"10.1373\/clinchem.2013.219881"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"TIROSH A, RUDICH A, SHOCHAT T, TEKES-MANOVA D, ISRAELI E, HENKIN Y, KOCHBA I, SHAI I: Changes in triglyceride levels and risk for coronary heart disease in young men. Ann Intern Med 18: 377-385, 2007.","DOI":"10.7326\/0003-4819-147-6-200709180-00007"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"VALDIVIELSO P, RAM\u00cdREZ-BOLLERO J, P\u00c9REZ-L\u00d3PEZ C: Peripheral arterial disease, type 2 diabetes and postprandial lipidaemia: Is there a link? World J Diabetes 5: 577-585, 2014a.","DOI":"10.4239\/wjd.v5.i5.577"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"VALDIVIELSO P, RAM\u00cdREZ-BUENO A, EWALD N: Current knowledge of hypertriglyceridemic pancreatitis. Eur J Intern Med 25: 689-694, 2014b.","DOI":"10.1016\/j.ejim.2014.08.008"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"VARBO A, NORDESTGAARD BG: Remnant cholesterol and ischemic heart disease. Curr Opin Lipidol 25: 266-273, 2014.","DOI":"10.1097\/mol.0000000000000093"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"VAVERKOV\u00c1 H, SOSKA V, ROSOLOV\u00c1 H, CESKA R, C\u00cdFKOV\u00c1 R, FREIBERGER T, PIT'HA J, POLEDNE R, STULC T, URBANOV\u00c1 Z, VR\u00c1BL\u00cdK M, CZECH ATHEROSCLEROSIS SOCIETY: Czech atherosclerosis society guidelines for the diagnosis and treatment of dyslipidemia in adults (in Czech). Cas Lek Cesk 146: II-XV, 2007.","DOI":"10.1016\/j.atherosclerosissup.2018.04.238"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"VRABLIK M, CESKA R: Treatment of hypertriglyceridemia: a review of current options. Physiol Res 64 (Suppl 3): S331-S340, 2015.","DOI":"10.33549\/physiolres.933199"},{"key":"ref33","unstructured":"WHITE BA: Hormonal regulation of energy metabolism. In: Berne and Levy Physiology (6th edition). KOEPPEN BM, STANTON BA (eds), Mosby Elsevier, Philadelphia, 2010, pp 668-675."},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"WYLER VON BALLMOOS MC, HARING B, SACKS FM: The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis. J Clin Lipidol 9: 498-510, 2015.","DOI":"10.1016\/j.jacl.2015.05.002"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"ZIMMERMAN R, LASS A, HAEMERLE G, ZECHNER R: Fate of fat: the role of adipose triglyceride lipase in lipolysis. Biochim Biophys Acta 1791: 464-500, 2009.","DOI":"10.1016\/j.bbalip.2008.10.005"}],"container-title":["Physiological Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T06:05:12Z","timestamp":1615356312000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomed.cas.cz\/physiolres\/pdf\/64%20Suppl%203\/64_S323.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,18]]},"references-count":36,"URL":"https:\/\/doi.org\/10.33549\/physiolres.933196","relation":{},"ISSN":["1802-9973","0862-8408"],"issn-type":[{"value":"1802-9973","type":"electronic"},{"value":"0862-8408","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11,18]]}}}